Document:

Exhibit
10.1

TERMINATION
AND RELEASE AGREEMENT

 

This Termination and Release Agreement (this “Agreement”) dated as of
March 4, 2002 (the “Effective Date”) is entered into by and
between SuperGen, Inc. (“SuperGen”), a California corporation with
a principal office at 4140 Dublin Boulevard, Suite 200, Dublin, California
94568, and Abbott Laboratories (“Abbott”), an Illinois corporation with a
principal office at 100 Abbott Park Road, Abbott Park, Illinois 60064.  SuperGen and Abbott are referred to herein
collectively as the “Parties” and individually as a “Party”.

 

                                WHEREAS, SuperGen and Abbott are
parties to the Worldwide Sales, Distribution, and Development Agreement between
SuperGen and Abbott, dated as of December 21, 1999 and as amended to date (the
“Sales Agreement”);

 

                                WHEREAS, SuperGen and Abbott are
parties to the Common Stock and Option Purchase Agreement between Abbott and
SuperGen, dated as of December 21, 1999 and as amended to date (the “Stock
Purchase Agreement”);

 

                      WHEREAS, SuperGen and Abbott are parties to the
U.S. Distribution Agreement between SuperGen and Abbott, dated as of December
21, 1999 and as amended to date (the “U.S. Distribution Agreement”);

 

                      WHEREAS, the Parties wish to terminate the
Sales Agreement and the Stock Purchase Agreement; and

 

                                WHEREAS, the Parties wish to release
any claims relating to the Sales Agreement and/or the Stock Purchase Agreement.

 

                                NOW, THEREFORE, the Parties agree as
follows:

 

1.       Definitions

 

1.1.                          “Affiliate” shall mean, with respect to
any entity, any other entity Controlling, Controlled by or under common Control
with the first entity.  For the purposes
of this Section 1.1, Control shall mean the ownership of 50% or more of any
class of capital stock of any entity, an interest in 50% or more of the profits
of any entity or the possession of the power to direct the activities of an
entity, whether by contract or otherwise.

 

2.       Termination and Release

 

2.1.                        Termination
of Sales Agreement.  In
consideration of mutual releases, covenants, agreements and/or other good and
valuable consideration, the receipt of which is hereby 

 

 

-1-

 

                                            acknowledged, the Parties agree to
terminate the Sales Agreement effective as of the Effective Date.

 

2.2.                        Termination
of Stock Purchase Agreement.  In
consideration of mutual releases, covenants, agreements and/or other good and
valuable consideration, the receipt of which is hereby acknowledged, the
Parties agree to terminate the Stock Purchase Agreement effective as of the Effective
Date.

 

2.3.                        SuperGen
Release of Abbott.  In
consideration of mutual releases, covenants, agreements and/or other good and
valuable consideration, the receipt of which is hereby acknowledged, SuperGen,
for itself and for its Affiliates and for its and their respective
administrators, successors, assigns, officers, directors, employees, and
trustees (all of the foregoing being referred to in this paragraph as “Releasors”)
release, acquit and forever discharge Abbott, its Affiliates and its and their
administrators, successors, assigns, officers, directors, employees, attorneys,
and trustees (all of the foregoing being referred to in this paragraph as “Releasees”)
from all obligations to the Releasors, including all unpaid milestone
obligations whether asserted or unasserted, arising under or relating to the
Sales Agreement or the Stock Purchase Agreement, including the termination
thereof, provided, however, that nothing contained herein is
intended to or shall release the Releasees from any and all obligations set
forth in this Agreement.

 

2.4.                        Abbott
Release of SuperGen. In consideration of mutual releases, covenants,
agreements and/or other good and valuable consideration, the receipt of which
is hereby acknowledged, Abbott, for itself and for its Affiliates and for its
and their respective administrators, successors, assigns, officers, directors,
employees, and trustees (all of the foregoing being referred to in this
paragraph as “Releasors”) release, acquit and forever discharge SuperGen,
its Affiliates and its and their respective administrators, successors,
assigns, officers, directors, employees, attorneys, and trustees (all of the
foregoing being referred to in this paragraph as “Releasees”) from all
obligations to the Releasors arising under or relating to the Sales Agreement
or the Stock Purchase Agreement, including the termination thereof, provided,
however, that nothing contained herein is intended to or shall release
the Releasees from any and all obligations set forth in this Agreement.

 

2.5.                        Fees
and Expenses.  The Parties
shall each bear the fees and expenses of its counsel and their own
out-of-pocket costs in connection with this Agreement.

 

3.       Settlement of Outstanding Fees

 

3.1.                        Development
Fees.  SuperGen currently owes
Abbott the sum of one million six hundred thousand dollars ($1,600,000) in
connection with development work that has been funded by Abbott under the Sales
Agreement (referred to herein as “Development Fees”).  The Development Fees shall be reimbursed by
SuperGen as follows: (i) eight hundred eighty thousand three hundred sixty-five
dollars ($880,365) shall be deducted from Abbott’s payment of fees owed to
SuperGen for 2001 fourth quarter sales of 

 

 

-2-

 

                                            Nipent® (Pentostatin) pursuant to
the U.S. Distribution Agreement; and (ii) the remaining seven hundred nineteen
thousand six hundred thirty-five dollars ($719,635) shall be paid by SuperGen
to Abbott within ten (10) days of the Effective Date.

 

3.2.                        Reconciliation.
 In the event SuperGen presents
evidence within thirty (30) days of the Effective Date, such evidence to be
reasonably acceptable to Abbott, that the amount of Development Fees set forth
in paragraph 3.1 is overstated, Abbott shall refund the amount of such overstatement
within thirty (30) days of the presentation of such evidence.

 

4.       WARRANTIES, LIMITATION OF LIABILITY AND
PUBLIC STATEMENTS

 

4.1.                        Limited
Warranties.  Each Party
hereby warrants that it has the right and authority to enter into and carry out
its obligations under this Agreement and that this Agreement has been
authorized by all requisite corporate action. 
Each Party hereby warrants that it shall not enter into any agreement in
conflict with this Agreement.

 

4.2.                        Public
Statements.  Each Party
hereby agrees not to make any public statement, oral or written, disparaging
the other Party with respect to any activity arising under or relating to the
Sales Agreement, the Stock Purchase Agreement or the U.S. Distribution
Agreement, provided that this Paragraph shall not apply to oral questions,
interrogatories, requests for information or other documents required in
connection with legal proceedings, subpoenas, civil investigations or other
similar processes.

 

5.       MISCELLANEOUS

 

5.1.                        Relationship
of the Parties.  Nothing
herein shall create any association, partnership, joint venture or the relation
of principal and agent between the Parties. 
Each Party is acting as an independent contractor, and no Party shall
have the authority to bind any other Party or its representatives in any way.

 

5.2.                        Entire
Agreement.  This
Agreement constitutes the entire agreement between the Parties with respect to
the subject matter hereof, and cancels and supercedes all prior negotiations,
understandings and agreements relating to the subject matter hereof.  The Parties represent and warrant that,
other than the U.S. Distribution Agreement, there is no other agreement or
contract relating to the termination of the Sales Agreement and/or the Stock
Purchase Agreement or any consideration transferred or to be transferred
between the Parties other than as set forth in this Agreement.

 

5.3.                        Waiver
and Amendment.  This
Agreement may not be amended except pursuant to a written instrument signed by
each of the Parties.  No right of a
Party, and no breach of any terms of this Agreement, can be waived and no
election under this Agreement can be made unless such waiver or election is in
writing and signed by the Party waiving such right or making such election.

 

 

-3-

 

5.4.                        Governing
Law.  This Agreement shall be
governed by the laws of the State of Illinois, without regard to the choice of
law principles thereof.

 

5.5.                        Construction
and Interpretation.  This
Agreement shall be deemed to have been jointly drafted by the Parties, no rules
of strict construction against either Party shall be applied.  In this Agreement, the word “including”
shall be deemed to be followed by “without limitation”.

 

5.6.                        Severability.  The provisions of this Agreement are
severable.  If any such provision shall
be held invalid or unenforceable for any reason, such provision shall be
replaced with a provision which accomplishes, to the extent possible, the
original business purpose of such provision in a valid and enforceable
manner.  The invalidity or
unenforceability of any provision of this Agreement shall not affect any other
provision of this Agreement.

 

5.7.                        Assignment.  Each of the Parties shall have the right to
assign its rights hereunder only to a surviving entity of a merger with such
Party, by operation of law.  This
Agreement shall be binding on and inure to the benefit of the Parties and their
respective successors and permitted assigns.

 

5.8.                        Notices.  Any notice given under this Agreement shall
be made in writing by registered mail, return receipt requested, or by
overnight courier, and shall be deemed given on the date received.

 

If
to SuperGen:                                     SuperGen,
Inc.

                                                                4140
Dublin Boulevard

                                                                Suite
200

                                                                Dublin,
California 94568

 

with
a copy to:                                      Wilson
Sonsini Goodrich & Rosati

                                                                650
Page Mill Road

                                                                Palo
Alto, California 94304-1050

 

If
to Abbott:                                          Abbott
Laboratories

                                                                200
Abbott Park Road

                                                                Abbott
Park, Illinois 60064, USA

                                                                Attention
of: President, Hospital Products Division

 

with
a copy to:                                      Abbott
Laboratories

                                                                Domestic
Legal Operations, Dept. 322, Bldg. AP-6

                                                                100
Abbott Park Road

                                                                Abbott
Park, Illinois 60064, USA

 

 

-4-

 

5.9.                        Counterparts.  This Agreement may be executed by facsimile
and in one or more counterparts, each of which shall be deemed to be an
original and all of which together shall constitute the same agreement.

 

                      ******************

 

                      IN WITNESS WHEREOF, the
Parties have executed this Agreement as of the Effective Date.

 

	
  Abbott Laboratories

  	
   

  	
  SuperGen, Inc.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ CHRISTOPHER BEGLEY

  	
   

  	
  By:

  	
  /s/ JOSEPH RUBINFELD

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Christopher Begley

  	
   

  	
  Name:

  	
  Joseph Rubinfeld

  
	
  Title:

  	
  President Hospital
  Products Division

  	
   

  	
  Title:

  	
  President and Chief
  Executive Officer

  
								

 

 

-5-<Page>

                                                                  Exhibit 10(30)
                               SECOND AMENDMENT TO
                             2001 RESTATEMENT OF THE
                          HARRAH'S ENTERTAINMENT, INC.
                       EXECUTIVE SUPPLEMENTAL SAVINGS PLAN

                  WHEREAS, Harrah's Entertainment, Inc. (the "Company")
maintains the 2001 Restatement of the Harrah's Entertainment, Inc. Executive
Supplemental Savings Plan (the "Plan") in order to provide its key executives
with an opportunity and incentive to save for retirement and other purposes; and

                  WHEREAS, it is desirable to amend the Plan to provide (i) that
participants may elect to defer up to 25% of their salary during any deferral
period, (ii) that any before-tax deferrals by a participant into the Company's
Savings and Retirement Plan (up to 6% of the participant's salary) which cannot
be deferred under that plan on a before-tax basis as a result of any law or
regulation will be automatically deferred under the Plan and that such deferrals
shall not be subject to the 25% limit on deferrals of salary, (iii) that
participants who at the request of the Company transfer their employment to JCC
Holding Company or one of its subsidiaries will continue to be participants in
the Plan for purposes of continued vesting, timing of distributions and
eligibility for certain Company enhancement contributions and (iv) that the
Trust Fund will be fully funded immediately before any Change of Control; and

                  WHEREAS, Section 12.1(a) of the Plan provides that the Company
has the right to amend the Plan; and

                  WHEREAS, Section 9.9 of the Plan provides that any action to
be taken by the Company shall be taken by its Board of Directors or the
appropriate committee of its Board of Directors; and

                  WHEREAS, the Human Resources Committee of the Company's Board
of Directors has approved the adoption of this Second Amendment.

                  NOW, THEREFORE, BE IT RESOLVED, that the Plan is hereby
amended, effective January 1, 2002, except as otherwise provided below, as
follows:

                  1. By substituting the following for the first sentence of
Section 3.5 of the Plan:

                     "If a former Employee is rehired by an Employer and is
eligible to participate in the Plan, he shall reenter the

<Page>

Plan on the same basis as a newly eligible Employee in accordance with the
provisions of Section 3.1 (SELECTION OF PARTICIPANTS)."

                  2. By substituting for Sections 4.1(a) and (b) of the Plan as
                     follows:

                     "(a) SALARY DEFERRAL CONTRIBUTIONS. A Participant may elect
to defer a maximum of 25% of the Salary otherwise payable to him during the
Deferral Period, or such other maximum amount as may be prescribed by the EDCP
Committee as the Salary Deferral Contribution limit for all Participants or
pursuant to subsection (c); PROVIDED, HOWEVER, that Savings and Retirement Plan
Rollover Deferrals pursuant to subsection (d) below shall be in addition to any
Salary Deferral Contributions permitted under this subsection (a)."

                  3. By inserting new Section 4.1(d) to the Plan as follows:

                     "(d) SAVINGS AND RETIREMENT PLAN ROLLOVER DEFERRALS. In
addition to the deferrals permitted under subsection (a) above, any Participant
that participates at the maximum before-tax percentage contributions under the
Savings and Retirement Plan shall be deemed to have elected to defer into this
Plan as a Savings and Retirement Plan Rollover Deferral that portion of eligible
Savings and Retirement Plan earnings which the Participant elected to defer
under such Savings and Retirement Plan which could not be deferred on a
before-tax basis under any such plan due to any law or regulation, but excluding
any amount which was actually deferred into the Savings and Retirement Plan but
distributed back to the Participant in a following plan year."

                  4. By substituting for Section 4.2 of the Plan as follows:

                     "4.2 MATCHING CONTRIBUTIONS.

                          (a) Each Employer shall make a Matching Contribution
on behalf of each of its Participants who has elected to make Salary Deferral
Contributions or has had any Savings and Retirement Plan Rollover Deferrals
pursuant to Section 4.1(d) during the Deferral Period under Section 4.1
(PARTICIPANT CONTRIBUTIONS) and is eligible to receive a matching contribution
under the Savings and Retirement Plan. No Matching Contributions shall be made
with respect to Bonus Deferral Contributions. The Matching Contribution shall be
credited to each eligible Participant's Matching Contribution

                                       2

<Page>

Account as of the year-end Valuation Date or date of termination.

                          (b) The Matching Contribution for each eligible
Participant shall equal the difference between

                              (1)      the sum of

                                       (A)   100% of the Participant's
                     contributions to the Savings and Retirement Plan for its
                     plan year coinciding with the Deferral Period, plus

                                       (B)   100% of the Participant's Salary
                     Deferral Contributions and Savings and Retirement Plan
                     Rollover Deferrals in the Deferral Period,

up to the Matching Limit as applied to the Participant's Salary, less

                              (2) the Employer's matching contribution for such
                  Participant under the Savings and Retirement Plan."

                  5. By substituting for Section 13.5 of the Plan as follows:

                     "13.5 FUNDING UPON A CHANGE OF CONTROL.  Immediately before
the occurrence of a Change of Control, the Company shall determine whether, for
any reason, the assets of the Trust Fund are less than the aggregate Account
balances of all Participants (determined without regard to the vested interest
of each Participant) and transfer an amount equal to the deficiency to the
Trustee of the Trust. If it is discovered at any time that the amount initially
transferred is less than the total amount called for by the preceding sentence,
the shortfall, including any accrued interest on the shortfall, shall be
transferred to the Trustee immediately upon the discovery of such error."

                  6. Effective as of January 1, 2001, by adding the attached
                     Appendix I to the Plan.

                                       3

<Page>

                  IN WITNESS WHEREOF, the Company has caused this Second
Amendment to be executed by a duly authorized officer on this 20th day of
November, 2001.

                                                  HARRAH'S ENTERTAINMENT, INC.

                                                  By: /s/ MARILYN G. WINN
                                                      --------------------

                                                  Name: Marilyn G. Winn
                                                  Title: SVP Human Resources

                                       4

<Page>

                                   APPENDIX I

                  This Appendix I amends the provisions of the Plan as
applicable to JCC Participants and is effective with respect to a Participant
upon employment by JCC of such Participant as a JCC Participant.

                  1.       DEFINITIONS.

                            (a) "JCC" means JCC Holding Company and its
subsidiaries.

                            (b) "JCC PARTICIPANT" means each Participant in the
Plan who is no longer employed by an Employer but who is an employee of JCC and
whose employment with an Employer and subsequent employment with JCC was
initiated at the request of the Company.

                            (c) "JCC SAVINGS AND RETIREMENT PLAN" means the
retirement plan qualified under Section 401(a) and 401(k) of the Internal
Revenue Code of 1986, as amended, in which employees of JCC and its subsidiaries
participate.

                            (d) "YEARS OF VESTING SERVICE" with respect to a JCC
Participant shall mean the years of service credited to an individual for
vesting purposes under the Savings and Retirement Plan, determined in accordance
with all applicable provisions of the Savings and Retirement Plan, and the JCC
Savings and Retirement Plan, determined in accordance with all applicable
provisions of the JCC Savings and Retirement Plan to the extent not inconsistent
with the Savings and Retirement Plan.

                  2.        NO TERMINATION OF EMPLOYMENT.

                  Participants in the Plan who become JCC Participants shall not
be treated as having terminated their employment with an Employer for purposes
of Sections 3.4, 4.7(b)(1), or 5.4(c) or Articles 7, or 8 of the Plan until the
earlier to occur of :

                            (a) the date the JCC Participant's employment with
JCC and its subsidiaries is terminated; provided JCC Participant is not
re-employed by the Company or any Affiliate, or

                            (b) the date the Company no longer holds a direct or
indirect equity ownership interest in JCC.

<Page>

                  3.        CONTRIBUTIONS.

                            (a) JCC Participants may not make Salary Deferral
Contributions or Savings and Retirement Plan Rollover Deferrals to the Plan.

                            (b) JCC Participants shall not be entitled to
receive any Discretionary Contributions.

                            (c) Each JCC Participant who received an initial
Enhancement Contribution as described in subsection 4.7(a) of the Plan shall be
credited with the second Enhancement Contribution under subsection 4.7(b)(1) if
he continues to be employed by, or receives salary continuation payments from
JCC until the date he attains age 55 and has completed 10 Years of Service.

                  4.        TERMINATION. The terms of this Appendix I shall
terminate and shall no longer be in effect as to any JCC Participant on the
earlier of (a) the date this Appendix I is otherwise terminated by the Company,
or (b) the date the Company no longer holds directly or indirectly any equity
ownership interest in JCC.

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]